ESElena N. Sholokhova

Elena N. Sholokhova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elena N. Sholokhova has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Lymphoid populations and tumor disseminated cells in the bone marrow in early breast cancer

    by Svetlana V. Chulkova, Elena N. Sholokhova, Olga P. Kolbatskaya, Irina A. Gladilina, Angelina V. Egorova, Ivan S. Stilidi, Tatiana N. Zabotina

    Background. The study of lymphoid populations is a necessary step for understanding the interaction between the tumor and the immune system, as well as for a detailed analysis of the persistence of tumor cells in the bone marrow of patients with breast cancer. Lymphoid populations of the bone marrow can serve as a potential point of application for immunotherapy. Aim. To study the composition of lymphoid populations and assess the relationship with disseminated tumor cells in the bone marrow of patients with operable breast cancer Materials and methods. The study included 65 bone marrow samples obtained by sternal puncture in patients with breast cancer. Ductal adenocarcinoma stage T1 / T2, N0 status prevailed. Luminal A was detected in 51.3 %, luminal B 10.3 %, Erb-B2 overexpressing subtype was established in 15.4 % and triple-negative subtype in 6.4 %. T cells (CD3), B cells (CD19), NK cells (CD56+CD3– ), minor populations of TCRγδ and TCRαβ lymphocytes, CD4+CD25+ T cells, subpopulations of CD10+, CD38+, CD5+ B cells were studied. CD45+EpCAM+ cells among myelokaryocytes of a bone marrow sample were assessed. An immunological study of bone marrow using monoclonal antibodies (Becton Diskinson, USA) was performed on a FACS Canto II flow cytometer. The results were analyzed using the Kaluza Analysis v.2.1 program. Results. A relationship was established between CD19+CD10+ cells and the morphological type of breast cancer: their increased content was noted in ductal adenocarcinoma (p ≤0.05). There was a relationship between lymphogenous metastasis and the level of CD5+CD38+ cells (p ≤0.05). In high-grade cancer, there was an increase in the proportion of CD4+CD25+ cells, estrogen-positive tumors were distinguished by the predominance of NK cells in the bone marrow (p ≤0.05). T-lymphoid populations are associated with the presence of disseminated tumor cells in the bone marrow. An increase in the proportion of CD4+CD25+ with a decrease in the number of CD3+HLA-DR+ and B-cells was noted (p = 0.03). Conclusion. Lymphoid populations of the bone marrow are associated with the morphological characteristics of breast cancer. In metastatic bone marrow lesions, the proportion of T-cell lymphoid populations changes and the number of B-cells decreases.

  • Open Access

    Correlation of CD71 transferrin receptor expression with ICAM-1 adhesion molecule expression by breast cancer cells

    by S. V. Chulkova, E. N. Sholokhova, I. V. Poddubnaya, I. S. Stylidi

    Background. Transferrin receptor 1 (CD71) plays a vital role in regulating cellular iron import. Cancer cells aberrantly express transferrin receptor 1 (CD71). Expression of CD71 receptors influences many aspects of tumorigenesis. Studying the expression of CD71 in breast cancer cells may reveal the peculiarities of tumor biology in order to select a priority type of drug treatment.Aim. Study the CD71 phenotype of breast cancer cells and evaluate its relationship with adhesion molecules.Materials and methods. We studied tumor samples obtained from breast cancer patients who were treated at the N.N. Blokhin National Medical Research Center of Oncology. On cryostat sections of the tumor, the CD71 phenotype (transfecrrin receptors), CD54 phenotype (intercellular adhesion molecule ICAM-1), and CD29 phenotype (common β-subunit of VLA antigens) were assessed using immunofluorescence. A ZEISS luminescent microscope (AXIOSKOP, Germany) was used. The assessment was performed using a semi-quantitative method: two types of positive reaction were identified according to Hammerling (mosaic and monomomorphic). Using contingency tables (Fisher’s exact test or Pearson’s χ2 test), the correlation between the expression of transferrin receptor molecules and adhesion molecules was studied.Results. The phenotype of breast cancer corresponded to CD71 monomorphic, which was noted in 64.4 % of samples (n = 61). Adhesion molecules were expressed in the majority of samples. β-1 CD29 integrins are presented monomorphically in 51.6 %. Expressing tumor adhesion molecules ICAM-1 in 37 cases showed a monomorphic type of receptor expression, and in 17 cases – mosaic. The expression of CD71 molecules was significantly associated with the expression of CD54 adhesion receptors. This was that CD71 positive tumors more often demonstrated expression of the CD54 receptor and this was expressed in a monomorphic type of reaction, which was 33 % versus 10.5 % (0.293, p = 0.008). With the mosaic CD71 phenotype, the proportion of tumors mosaically expressing CD29 β1-integrin molecules was 80.0 %, while with the CD71 monomorphic phenotype it was 33.3 %, in most cases (52.4 %) tumors with monomorphic expression of CD29 were observed (versus 20.0 % for mosaic phenotype).Conclusion. Breast cancer cells are characterized by an overexpression phenotype of CD71, which is correlated with the expression of CD54 adhesion molecule (ICAM-1). The monomorphic expression of β1-integrin molecules, which occurs in CD71 positive tumors (with a monomorphic type of reaction), indicates that these cells have a higher metastatic potential.

  • Expression of transferrin receptor 1 and β1-integrins correlates with estrogen receptor status and immune infiltration in breast cancer

    by S.V. Chulkova, E.N. Sholokhova, I.V. Poddubnaya, I.A. Gladilina, A.V. Egorova, I.S. Stilidi

    Cancer cells can aberrantly express various markers, including transferrin receptor 1 (CD71) and β1-integrin molecules. Their role in invasion, migration and metastasis has been demonstrated. Determination of their expression in breast cancer (BC) may be an important point to characterize the clinical course of the tumor and prognosis of the disease. Objective. To study of transferrin receptor 1 (CD71) expression by primary breast cancer cells in correlation with tumor cell phenotype. Material and methods. Determination of BC phenotype: immunohistochemical staining method (immunofluorescence). Antibodies to ER (estrogen receptors), KL-1 (pancytokeratin), CD71 (transferrin receptor), CD29 (β1-integrins). CD45, CD3, CD4, CD8, CD20 infiltration was also evaluated. ZEISS microscope (AXIOSKOP; Germany), method of G.J. Hammerling et al. Statistical processing: IBM-SPSS Statistics v.21. Results. 63% of BC cases had CD71+ phenotype. CD71-mosaic tumors were observed in 14.4%. β1-integrin expression was monomorphic in 51.6% of cases and mosaic in 38.7%. 85% of ER-positive tumors were CD71-positive with a monomorphic type of reaction; p=0.014. Among ER-negative tumors, CD71-negative reactions were 2-fold more frequent and the monomorphic type was less frequent. ER-positive tumors were CD29-positive in 73%; p=0.031. 45.5% of ER+ tumors were CD29-monomorphic. Among ER-negative tumors, the frequency of CD29-monomorphic tumors was 55%. Significant infiltration by CD3+ cells was predominant in CD71-positive tumors; p=0.016. In the CD29-monomorphic phenotype, CD45+ infiltration was 31.3%, and in the mosaic phenotype, 67.1%. Conclusion. BC aberrantly expresses transferrin receptors, β1-integrins. CD71 expression is associated with ER expression. ER-positive tumors are often monomorphic for CD71. Prominent CD3+ infiltration was present in CD71+ tumors. Expression of β1-integrins correlated with ER+ status and weak immune infiltration.

  • Open Access

    Interrelation of HLA-I and class II major histocompatibility complex molecules with clinical and morphological signs of breast cancer: A retrospective cohort study

    by Svetlana V. Chulkova, Elena N. Sholokhova, Irina V. Poddubnaya, Ivan S. Stilidi, Dmitrii A. Burov, Nikolai N. Tupitsyn

    Background. For a long time, interest in the HLA peptide complex is unabated, the clinical significance of which in cancer is still the subject of intense debate. Through the presentation of HLA antigens, tumor cells become available for recognition and destruction by effector cells of the immune system. A detailed analysis of the expression status of HLA molecules by breast cancer cells is of both scientific and important practical value. It can provide additional information about the immune system to determine a further strategy for treating breast cancer. Aim. To evaluate the frequency of expression of HLA-I and class II molecules by breast cancer cells and to determine its relationship with the morphological and clinical characteristics of the tumor. Materials and methods. This study included 82 patients with breast cancer who received treatment at the Blokhin National Medical Research Center of Oncology. Immunophenotyping of the primary tumor was performed by the immunohistochemical method (immunofluorescent staining) on cryostat sections. The reaction was evaluated using a ZEISS luminescent microscope (AXIOSKOP, Germany). The frequency of expression of HLA-I and class II molecules was studied depending on the clinical and morphological characteristics of breast cancer. Results. It was found that the frequency of expression of HLA I and II class molecules by breast cancer cells differed. HLA class I antigens are preserved in almost half of the cases 54.5%, while HLA class II antigens are preserved in 22.0%. Associations of molecules of the major histocompatibility complex with clinical and morphological signs of breast cancer were revealed. The frequency of HLA-DR negative cases increases in the stage advanсed (p=0.029). The frequency of monomorphic expression of HLA class II with T1 tumor was 50% versus 0% at T4 tumor (p=0.032). Estrogen receptor-negative tumors in most cases did not express HLA-II class (85.2% vs 64%; p=0.034). No connection with other clinical and morphological features of the tumor has been established. Conclusion. In most cases of breast cancer, the expression of HLA class II molecules is lost, while the expression of HLA class I is preserved in half of the cases. Monomorphic expression of HLA class II is characteristic of the early stage of breast cancer development and predominantly of receptor-positive tumors.


  • Open Access

    The relationship of lymphoid populations (infiltration) of the primary tumor with bone marrow immune responses in patients with breast cancer

    by S. V. Chulkova, E. N. Sholokhova, I. V. Poddubnaya, I. S. Stylidi, A. V. Egorova, N. A. Kozlov, N. N. Tupitsyn

    Backgraund. Currently, immunotherapy is firmly established in the standard of cancer treatment. The basis for the appointment of immunotherapy are immunological tumor markers, which include lymphoid infiltration, a detailed study of which has received increasing attention in the last decade. An undoubted interest is the study of lymphoid infiltration, not only depending on the morpho-clinical parameters of breast cancer (BC), but also on the immune system of the bone marrow.Aim. To evaluate the infiltration of the primary tumor by lymphocytes depending on the morpho-clinical characteristics of BC and immune responses in the bone marrow.Materials and methods. This study included 125 patients with BC who received treatment at the “N.N. Blokhin National Medical Research Center of Oncology” of the Ministry of Health of Russia. Tumor stage II was prevailed, а moderate degree of differentiation (G2) was more often noted. The luminal BC – 67 %, non-luminal – 33 %. Immunophenotyping of the primary tumor: cryostat sections, ZEISS Axioscope luminescent microscope (Zeiss AG, Germany). CD45+, CD38+, T- and B-cell infiltration were assessed. Bone marrow: CD3+, CD4+, CD8+, CD19+, CD16+, CD56+ lymphocytes and their subpopulations were studied (FACSCanto II flow cytometer, Kaluza Analysis v2.1 program (Beckman Coulter, USA)).Results. CD45+ infiltration was noted in 50.5 % of cases (severe in 30 %, moderate – 26.4 %). CD8+ cells significantly infiltrated the tumor in 21.4 % of cases. CD38+ infiltration was observed in 40 %. In the non-luminal BC, severe CD45 infiltration was observed more frequently than in the luminal (33 % vs 26 %). CD38+ infiltration is expressed in non-luminal BC (p = 0.016). CD45+ infiltration was positively correlated with earlier stages (p = 0.071) more pronounced in infiltrative ductal BC, than in lobular BC: 59.2 % vs 20 % (p = 0.05). The content of CD45RO+cells in bone marrow in the luminal BC is higher than in the non-luminal: 37.3 ± 2.3 % vs 28 ± 2.8 % (p = 0.04). The number of CD19+CD38+ cells, on the contrary, is less: 24.2 ± 2 % vs 34.8 ± 6 % (p = 0.041). Tumor-infiltrating lymphocytes highly correlated with bone marrow lymphoid populations: CD38+ cells with NK-bone marrow cells; CD4+ cells with the B-precursors; CD8+cells with the B1-lymphocytes.Conclusion. Lymphoid infiltration of BC is associated with stage, tumor size, histological type and biological subtype. Intratumoral populations CD38+, CD4+, CD3+, CD8+ cells are in a negative correlation with bone marrow lymphoid populations.


  • Open Access

    Expression of monomorphic HLA-determinants, transferrin receptor 1 (TfR1) in molecular subtypes of breast cancer

    by S. V. Chulkova, E. N. Sholokhova, I. V. Poddubnaya, I. S. Stylidi, N. N. Tupitsyn

    Background. Immunotropic drugs are widely used in the modern strategy of cancer treatment. Importance is given to immunological markers of the tumor, which determine the prognosis of the disease, the effectiveness of treatment. Therefore, the study of their expression is one of the leading scientific directions. Of particular interest is the study of monomorphic HLA determinants, transferrin receptor 1 (TfR1), depending on its biological subtype of breast cancer.Aim. To evaluate the frequency of expression of HLA class I, II, TfR1 molecules by breast cancer cells and determine their relationship with the molecular biological subtype of the tumor.Materials and methods. This study included 120 patients with breast cancer who received treatment at the N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia. Tumor stages II and III prevailed: 56.7 % and 33.4 %, respectively. A moderate degree of differentiation (G2) was more often noted. The luminal subtype was 58.3 % (n = 70), non-luminal – in 41.7 % (n = 50). Immunophenotyping of the primary tumor was performed by immunofluorescence on cryostat sections. The reaction was evaluated using a ZEISS Axioscope 5 luminescent microscope (Zeiss AG, Germany). The frequency of expression of HLA class I and II molecules were studied depending on the clinical and morphological characteristics of breast cancer. The frequency of expression of HLA class I, HLA-DR, TfR1, molecules, toumor infiltration of СD45+, CD38+, depending on the molecular subtype of breast cancer was studied.Results. It was found that the frequency of expression of monomorphic determinants of the HLA class I in luminal and non-luminal subtypes of breast cancer was comparable; HLA-DR was expressed significantly more often in the luminal subtype of breast cancer: 37.3 % and 18.0 %, respectively, p = 0.022. The frequency of TfR1 expression was significantly higher in the luminal subtype of cancer compared to non-luminal, p = 0.014. Predominantly monomorphic type of reaction was observed: in 76.5 % (n = 39) of cases. The mosaic type of the TfR1 reaction was noted in 7.8 % of the samples. TfR1 monomorphic expression was detected in 50.0 % (n = 30) of cases in non-luminal cancer, the mosaic expression – in 20.0 % (n = 12) of cases. A pronounced degree of lymphoid infiltration, in particular plasmacytic, was established in non-luminal subtype of breast cancer: 70.7 % (n = 29) and 35.0 % (n = 14), respectively, p = 0.001. An association was noted between the expression of HLA I class molecules and the severity of general leukocyte infiltration, p = 0.007.Conclusion. The frequency of expression of HLA class I monomorphic determinants did not differ in molecular subtypes of breast cancer. The expression of the HLA class II molecule was significantly more frequently observed in the luminal subtype of breast cancer. The expression of HLA class I monomorphic determinants is associated with the degree of lymphoid infiltration of the tumor. In the non-luminal subtype, plasmacytic infiltration is more pronounced. The expression of transferrin receptors is significantly more pronounced in the luminal subtype.


  • Open Access

    The analysis of the relationship between transferrin receptor 1 (TfR1) and clinical, morphological and immunophenotypic characteristics of breast cancer: retrospective cohort study

    by Svetlana V. Chulkova, Elena N. Sholokhova, Irina V. Poddubnaya, Ivan S. Stilidi, Nikolai N. Tupitsyn

    Background. Transferrin receptor 1 (TfR1) expression has been identified in a number of malignant tumors. It is noted that its overexpression gives growth advantages to cancer cells. Estimation of transferrin receptor expression in breast cancer (BC) might be an important component in disease prognosis, choice of treatment, also might be an attractive target for targeted therapy. Aim. To evaluate the expression of TfR1 by BC cells and to study its relationship with the clinical, morphological and immunophenotypic characteristics of the tumor. Materials and methods. This study included 82 patients with BC who received treatment at the Blokhin National Medical Research Center of Oncology (Moscow). The expression of TfR1 on primary tumor cells was studied, the relationship of TfR1 with clinical, morphological and immunophenotypic characteristics of BC was analyzed. Immunophenotyping of the primary tumor was performed by the immunohistochemical method (immunofluorescent staining) on cryostat sections. Antibodies to CD71, CD95, CD54, CD29, MUC1, Pgp170 were used. The reaction was evaluated using a luminescent microscope (AXIOSKOP, Germany). The study was dominated by patients with stage IIB 54% and IIIB 21%. Infiltrative ductal BC was diagnosed in 67% (n=55) of patients, infiltrative-lobular in 22% (n=18) of cases, other types in 11.0% (n=9). Results. BC cells expressed TfR1 in most cases (64.4%; n=61). A combination of TfR1 monomorphic expression with MUC1 monomorphic expression (74.4%; n=47) was noted. CD29 is presented both mosaic (38.7%) and monomorphic (51.6%). The Pgp170 antigen was monomorphically observed in 27.5% of cases. As the proportion of TfR+ cells increased, the expression frequency of the adhesion molecule CD54 increased from 10.5 to 33.3%, a positive correlation was established (r=0.293; p=0.008). In the group with TfR1 monomorphic expression, the frequency of tumors expressing the CD95 apoptosis molecule decreased: 25.0% vs 13% (p=0.042). Conclusion. BC cells overexpress TfR1. TfR1 expression is associated with tumor immunophenotype.


  • Open Access

    HLA-monomorphic determinants of the primary tumor in breast cancer patients

    by S. V. Chulkova, E. N. Sholokhova, I. V. Poddubnaya, I. S. Stylidi, N. N. Tupitsyn

    Background. Molecules of the major histocompatibility complex in cancer are currently being widely studied, and their clinical significance is still the subject of controversy. It is reported that they might have an important predictive value in the effectiveness of immunotherapy. The study of the expression HLA molecules status in breast cancer provides a deeper understanding of the biological properties of the tumor, in particular to identify the features of its immunological phenotype, which may further influence on breast cancer therapy.Aim. To evaluate the frequency of HLA-immunophenotypes in breast cancer and their relationship with the clinical and morphological features of the primary tumor.Materials and methods. This study included 82 patients with breast cancer who received treatment at the N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia. Immunophenotyping of the primary tumor was performed by immunofluorescence on cryostat sections. The reaction was evaluated using a ZEISS Axioscope 5 luminescent microscope (Zeiss AG, Germany). The study was dominated by patients with stage IIB 54 %, stage IIA was detected in 5 % of cases, IIIA – in 12 % of cases, IIIB – in 21 % of cases, IIIC – 8 %. Infiltrative ductal breast cancer was diagnosed in 67 % of patients (n = 55), infiltrative-lobular – in 22 % of cases (n = 18), other types – in 11 % (n = 9). The frequency of immunophenotypes was studied depending on the clinical and morphological characteristics of breast cancer.Results. It was found that in the group as a whole, the HLA-binegative immunophenotype of breast cancer was predominant. It dominated at stage T4 compared to the HLA-I+/HLA-DR+ phenotype (100 and 0 %), p = 0.042. At the same time, it should be noted that in T4 primary tumor the HLA-I+/HLA-DR– immunophenotype was also observed. The relationship this immunophenotype was noted with the stage: frequency at stage IIIA was higher than the HLA-I+/HLA-DR+ phenotype, 60 and 40 %, p = 0.01. Both HLA-DR-negative immunophenotypes were characterized by a high incidence of lymph node involvement and the absence of estrogen receptor expression. 80 % of receptor-negative tumors were noted in HLA-binegative immunophenotype compared to phenotype HLA-I+/HLA-DR+, p = 0.022; the similar data were obtained for the HLA-I+/HLA-DR– immunophenotype (p = 0.037).Conclusion. HLA immunophenotypes analysis of breast cancer revealed the HLA-binegative immunophenotype of breast cancer was predominant. The second most common immunophenotype was the absence of expression of HLA-DR molecules. The association of HLA-immunophenotypes with the stage of the tumor process, the size of the primary tumor, and the expression status of estrogen receptors was revealed.